Drug Detail

Information about Telaglenastat

Generic Name	Telaglenastat
IND	CB-839
Brand Name (US)
Manufacturer	Calithera Biosciences, Inc
Drug Type	Small molecule
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	GIST Tumor Based
Strategy	Block related tumor signal paths
Drug Category	SDH-directed

Links
	Calithera Prgrams CB-839

	2014 AACR Poster

Trials of this drug
	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Trial results
	ASCO - GU - 2018 Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib(Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC)